The regional government of Queensland and the federal Australian Government have pledged a total of $13m to University of Queensland (UQ) to support the development of its Covid-19 vaccine candidate.

UQ’s Covid-19 vaccine was one of the first three candidates to receive funding from the Norwegian non-profit Coalition for Epidemic Preparedness Innovations (CEPI) in January. This partnership was extended to include California-based Dynavax Technologies in March.

CEPI injected up to $10.6m into UQ’s molecular clamp technology, which is patented by university-linked UniQuest.

The university hopes this new injection of funds will help cut the timeline for an effective vaccine against the Covid-19 pandemic from 18 months to one year. The researchers hope to initiate clinical trials by July.

The university’s School of Chemistry and Molecular Biosciences senior research fellow Dr Keith Chappell added: “The containment procedures being put in place within Australia and internationally will slow the spread of the virus and we want to use that time as effectively as possible.

“Accelerating our work to find a safe and effective vaccine brings us a step closer to translating a fundamental research discovery through to the full scale manufacture for the global populace.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.